VYGR · Categories · Form 4

VYGR - SEC Form 4 insider transactions

Voyager Therapeutics Inc. (VYGR) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for VYGR

• 27d
  SEC Form 4 filed by Sandrock Alfred

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 27d
  SEC Form 4 filed by Shiferman Gregory L.

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 64d
  COO & CBO Swartz Robin sold $24,347 worth of shares (6,458 units at $3.77), decreasing direct ownership by 3% to 199,738 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 64d
  President and CEO Sandrock Alfred sold $53,807 worth of shares (14,197 units at $3.79), decreasing direct ownership by 3% to 484,060 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 64d
  Chief Financial Officer Jorgensen Nathan D. sold $17,598 worth of shares (4,668 units at $3.77), decreasing direct ownership by 3% to 151,416 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 64d
  Chief Scientific Officer Carter Todd Alfred sold $15,694 worth of shares (4,174 units at $3.76), decreasing direct ownership by 3% to 145,718 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 69d
  COO & CBO Swartz Robin sold $13,354 worth of shares (3,882 units at $3.44), decreasing direct ownership by 2% to 206,196 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 69d
  Chief Scientific Officer Carter Todd Alfred sold $11,355 worth of shares (3,301 units at $3.44), decreasing direct ownership by 2% to 149,892 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 69d
  President and CEO Sandrock Alfred sold $40,006 worth of shares (11,732 units at $3.41), decreasing direct ownership by 2% to 498,257 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 78d
  COO & CBO Swartz Robin sold $17,591 worth of shares (4,569 units at $3.85), decreasing direct ownership by 2% to 210,078 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 78d
  President and CEO Sandrock Alfred sold $46,086 worth of shares (12,192 units at $3.78), decreasing direct ownership by 2% to 509,989 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 78d
  Chief Scientific Officer Carter Todd Alfred sold $13,571 worth of shares (3,525 units at $3.85), decreasing direct ownership by 2% to 153,193 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 79d
  Chief Medical Officer Ferguson Toby was granted 45,000 shares, increasing direct ownership by 32% to 183,914 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 79d
  Chief Scientific Officer Carter Todd Alfred was granted 33,000 shares, increasing direct ownership by 27% to 156,718 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 79d
  COO & CBO Swartz Robin was granted 45,000 shares, increasing direct ownership by 27% to 214,647 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 79d
  President and CEO Sandrock Alfred was granted 86,250 shares, increasing direct ownership by 20% to 522,181 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 79d
  Chief Financial Officer Jorgensen Nathan D. was granted 32,250 shares, increasing direct ownership by 26% to 156,084 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 112d
  SEC Form 4 filed by SVP and General Counsel Shiferman Gregory L.

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 205d
  Chief Financial Officer Jorgensen Nathan D. sold $36,643 worth of shares (7,666 units at $4.78), decreasing direct ownership by 6% to 123,834 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 253d
  Chief Medical Officer Ferguson Toby sold $70,870 worth of shares (19,000 units at $3.73), decreasing direct ownership by 12% to 138,914 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 330d
  SEC Form 4 filed by Director Vitale Nancy

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 330d
  SEC Form 4 filed by Director Scangos George A

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 330d
  SEC Form 4 filed by Director Pierce Glenn

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 330d
  SEC Form 4 filed by Director Onyia Jude

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 330d
  SEC Form 4 filed by Director Mackey Catherine J

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 330d
  SEC Form 4 filed by Director Hyman Steven

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 330d
  SEC Form 4 filed by Director Higgins Michael J

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 330d
  SEC Form 4 filed by Director Geraghty James A

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 330d
  SEC Form 4 filed by Director Colon Grace

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 391d
  Chief Medical Officer Ferguson Toby sold $34,595 worth of shares (10,086 units at $3.43), decreasing direct ownership by 6% to 157,914 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 391d
  President and CEO Sandrock Alfred sold $37,336 worth of shares (10,885 units at $3.43), decreasing direct ownership by 2% to 430,931 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 430d
  Chief Scientific Officer Carter Todd Alfred sold $14,079 worth of shares (3,305 units at $4.26) and was granted 46,000 shares, increasing direct ownership by 53% to 123,718 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 430d
  President and CEO Sandrock Alfred sold $49,616 worth of shares (11,702 units at $4.24) and was granted 145,000 shares, increasing direct ownership by 43% to 441,816 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 430d
  COO & CBO Swartz Robin sold $16,550 worth of shares (3,894 units at $4.25) and was granted 71,250 shares, increasing direct ownership by 66% to 169,647 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 430d
  Chief Legal Officer Fahey Sandell Jacquelyn was granted 41,500 shares, increasing direct ownership by 51% to 123,143 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 430d
  Chief Medical Officer Ferguson Toby was granted 63,000 shares, increasing direct ownership by 60% to 168,000 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 430d
  Chief Financial Officer Jorgensen Nathan D. was granted 51,500 shares, increasing direct ownership by 64% to 131,500 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 442d
  Chief Scientific Officer Carter Todd Alfred sold $24,088 worth of shares (5,413 units at $4.45), decreasing direct ownership by 6% to 81,023 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 442d
  COO & CBO Swartz Robin sold $30,928 worth of shares (6,950 units at $4.45), decreasing direct ownership by 6% to 102,291 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 442d
  President & CEO Sandrock Alfred sold $74,066 worth of shares (16,644 units at $4.45), decreasing direct ownership by 5% to 308,518 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 442d
  Chief Legal Officer Fahey Sandell Jacquelyn sold $19,393 worth of shares (4,358 units at $4.45), decreasing direct ownership by 5% to 81,643 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 470d
  COO & CBO Swartz Robin sold $15,713 worth of shares (3,087 units at $5.09), decreasing direct ownership by 3% to 109,241 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 470d
  Chief Scientific Officer Carter Todd Alfred sold $6,110 worth of shares (1,191 units at $5.13), decreasing direct ownership by 1% to 86,436 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 490d
  COO&CBO Swartz Robin sold $36,725 worth of shares (6,500 units at $5.65), decreasing direct ownership by 5% to 112,328 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 574d
  Chief Legal Officer Fahey Sandell Jacquelyn sold $34,914 worth of shares (5,999 units at $5.82), decreasing direct ownership by 7% to 86,001 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 575d
  Chief Financial Officer Jorgensen Nathan D. was granted 80,000 shares (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 660d
  SEC Form 4 filed by Chief Financial Officer Jorgensen Nathan D.

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 692d
  SEC Form 4 filed by Vitale Nancy

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 692d
  SEC Form 4 filed by Scangos George A

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 692d
  SEC Form 4 filed by Pierce Glenn

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 692d
  SEC Form 4 filed by Onyia Jude

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 692d
  SEC Form 4 filed by Mackey Catherine J

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 692d
  SEC Form 4 filed by Hyman Steven

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 692d
  SEC Form 4 filed by Higgins Michael J

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 692d
  SEC Form 4 filed by Geraghty James A

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 692d
  SEC Form 4 filed by Colon Grace

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 757d
  Ferguson Toby was granted 105,000 shares (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 757d
  Swartz Robin sold $13,407 worth of shares (1,357 units at $9.88), decreasing direct ownership by 1% to 117,004 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 757d
  Sandrock Alfred sold $119,454 worth of shares (12,115 units at $9.86), decreasing direct ownership by 4% to 322,839 units (SEC Form 4)

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
• 765d
  SEC Form 4 filed by Ferguson Toby

  4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

Other VYGR categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends